Roche’s Alecensa Latest Beneficiary of Faster China Drug Approvals

ZURICH – Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans.

FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company’s headquarters in Basel February 4, 2009. REUTERS/Christian Hartmann (SWITZERLAND)/File Photo

China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.

– Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *